Sarah B Peskoe1, Corinne E Joshu1, Sabine Rohrmann2, Katherine A McGlynn3, Sarah J Nyante3, Gary Bradwin4, Adrian S Dobs5,6, Norma Kanarek6,7, William G Nelson6,7,8, Elizabeth A Platz1,6,8. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 2. Department of Chronic Disease Epidemiology; Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland. 3. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland. 4. Department of Laboratory Medicine, Harvard Medical School and Children's Hospital, Boston, Massachusetts. 5. Division of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 6. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. 7. Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 8. Department of Urology and the James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract
BACKGROUND: The association between serum sex steroid hormones and PSA in a general population has not been described. METHODS: Included were 378 men aged 40-85 years who participated in the National Health and Nutrition Examination Survey in 2001-2004, who did not have a prostate cancer diagnosis, and had not had a recent biopsy, rectal examination, cystoscopy, or prostate infection or inflammation. Serum total PSA, total testosterone, androstanediol glucuronide (3α-diol-G), estradiol, and sex hormone binding globulin (SHBG) concentrations were previously measured. Free testosterone was estimated by mass action. We applied sampling weights and calculated geometric mean PSA concentration by hormone quintiles adjusting for age and race/ethnicity, and also for body mass index, waist circumference, smoking, diabetes, and mutually for hormones. We estimated the OR of PSA ≥2.5 ng/ml per hormone quintile using logistic regression. RESULTS: Geometric mean PSA increased across testosterone quintiles after age and race/ethnicity (Q1: 0.80, Q5: 1.14 ng/ml; P-trend = 0.002) and multivariable (Q1: 0.79, Q5: 1.16 ng/ml; P-trend = 0.02) adjustment; patterns were similar for free testosterone and 3α-diol-G. SHBG was inversely associated with PSA only after multivariable adjustment (Q1: 1.32, Q5: 0.82 nmol/L; P-trend = 0.01). Estradiol and PSA were not associated. The OR of PSA ≥2.5 ng/ml was 1.54 (95% CI 1.18-2.01) per testosterone quintile after age and race/ethnicity adjustment, and 1.78 (95% CI 1.16-2.73) after multivariable adjustment. CONCLUSIONS: In this nationally representative sample, men with higher testosterone had higher PSA even after taking into account other hormones and modifiable factors. Men with higher SHBG had lower PSA, but only after multivariable adjustment.
BACKGROUND: The association between serum sex steroid hormones and PSA in a general population has not been described. METHODS: Included were 378 men aged 40-85 years who participated in the National Health and Nutrition Examination Survey in 2001-2004, who did not have a prostate cancer diagnosis, and had not had a recent biopsy, rectal examination, cystoscopy, or prostate infection or inflammation. Serum total PSA, total testosterone, androstanediol glucuronide (3α-diol-G), estradiol, and sex hormone binding globulin (SHBG) concentrations were previously measured. Free testosterone was estimated by mass action. We applied sampling weights and calculated geometric mean PSA concentration by hormone quintiles adjusting for age and race/ethnicity, and also for body mass index, waist circumference, smoking, diabetes, and mutually for hormones. We estimated the OR of PSA ≥2.5 ng/ml per hormone quintile using logistic regression. RESULTS: Geometric mean PSA increased across testosterone quintiles after age and race/ethnicity (Q1: 0.80, Q5: 1.14 ng/ml; P-trend = 0.002) and multivariable (Q1: 0.79, Q5: 1.16 ng/ml; P-trend = 0.02) adjustment; patterns were similar for free testosterone and 3α-diol-G. SHBG was inversely associated with PSA only after multivariable adjustment (Q1: 1.32, Q5: 0.82 nmol/L; P-trend = 0.01). Estradiol and PSA were not associated. The OR of PSA ≥2.5 ng/ml was 1.54 (95% CI 1.18-2.01) per testosterone quintile after age and race/ethnicity adjustment, and 1.78 (95% CI 1.16-2.73) after multivariable adjustment. CONCLUSIONS: In this nationally representative sample, men with higher testosterone had higher PSA even after taking into account other hormones and modifiable factors. Men with higher SHBG had lower PSA, but only after multivariable adjustment.
Authors: Giovanni Corona; Valentina Boddi; Francesco Lotti; Mauro Gacci; Marco Carini; Giulia De Vita; Alessandra Sforza; Gianni Forti; Edoardo Mannucci; Mario Maggi Journal: J Sex Med Date: 2009-11-13 Impact factor: 3.802
Authors: Gabriella M Anic; Demetrius Albanes; Sabine Rohrmann; Norma Kanarek; William G Nelson; Gary Bradwin; Nader Rifai; Katherine A McGlynn; Elizabeth A Platz; Alison M Mondul Journal: Clin Endocrinol (Oxf) Date: 2016-04-06 Impact factor: 3.478
Authors: Alexander W Pastuszak; Lissette P Gomez; Jason M Scovell; Mohit Khera; Dolores J Lamb; Larry I Lipshultz Journal: Sex Med Date: 2015-08-12 Impact factor: 2.491
Authors: Rhonda Arthur; Henrik Møller; Hans Garmo; Lars Holmberg; Pår Stattin; Håkan Malmstrom; Mats Lambe; Niklas Hammar; Göran Walldius; David Robinson; Ingmar Jungner; Mieke Van Hemelrijck Journal: Cancer Med Date: 2016-02-29 Impact factor: 4.452
Authors: Rachel Dankner; Paolo Boffetta; Lital Keinan-Boker; Ran D Balicer; Alla Berlin; Liraz Olmer; Havi Murad; Barbara Silverman; Moshe Hoshen; Laurence S Freedman Journal: Diabetologia Date: 2016-05-17 Impact factor: 10.122